Related Experiment Video

Updated: Aug 29, 2025

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
10:43

Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids

Published on: December 23, 2022

3.5K

Targeting Aberrant Histone Posttranscription Modification Machinery in Esophageal Squamous Cell Carcinoma: Current

Gang Ma1, Tongyang Gong2, Zhihua Liu2

  • 1Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.

Research (Washington, D.C.)
|September 8, 2022
PubMed

Insights

Targeted therapies for esophageal squamous cell carcinoma (ESCC) are limited. Histone posttranscription modifications (PTM) offer potential druggable targets for treating this aggressive cancer, with ongoing research into their role.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Esophageal squamous cell carcinoma (ESCC) is an aggressive cancer with limited effective targeted therapies.
  • Survival rates for ESCC have remained stagnant due to a lack of treatment options.
  • Histone posttranscription modifications (PTMs) are crucial epigenetic regulators implicated in cancer development.

Purpose of the Study:

  • To review the current understanding of histone PTMs in ESCC.
  • To identify deregulations in histone PTM machinery that drive ESCC.
  • To highlight potential druggable targets within histone PTM pathways for ESCC treatment.

Main Methods:

  • Literature review of recent studies on histone PTMs in ESCC.
  • Analysis of epigenetic alterations in ESCC.
  • Identification of therapeutic targets based on PTM dysregulation.

Main Results:

  • Deregulations in histone PTM machinery are identified as drivers of malignant phenotypes in ESCC.
  • Specific histone PTMs are implicated in the progression of esophageal squamous cell carcinoma.
  • These epigenetic alterations present novel therapeutic avenues.

Conclusions:

  • Histone PTMs represent a promising area for developing targeted therapies for ESCC.
  • Further research is needed to overcome challenges and translate findings into clinical practice.
  • Targeting epigenetic modifications could improve outcomes for patients with esophageal squamous cell carcinoma.

More Related Videos

Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

524
Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues05:57

Establishment and Histological Analysis of Esophageal Organoids Modeling the Progression from Normal to Cancerous Tissues

Published on: May 30, 2025

422

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Spreading of Chromatin Modifications02:25

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Histone Modification02:32

Histone Modification

3.5K